ROCE Insights For Biolase
Biolase (NASDAQ: BIOL) reported Q3 sales of $6.54 million. Earnings fell to a loss of $3.67 million, resulting in a 7.84% decrease from last quarter. In Q2, Biolase brought in $2.94 million in sales but lost $3.98 million in earnings.
What Is ROCE?
Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q3, Biolase posted an ROCE of -0.26%.
Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.
Return on Capital Employed is an important measurement of efficiency and a useful tool when comparing companies that operate in the same industry. A relatively high ROCE indicates a company may be generating profits that can be reinvested into more capital, leading to higher returns and growing EPS for shareholders.
For Biolase, the return on capital employed ratio shows the current amount of assets may not actually be helping the company achieve higher returns, a note many investors will take into account when making long-term financial decisions.
Q3 Earnings Insight
Biolase reported Q3 earnings per share at $-0.21/share, which did not meet analyst predictions of $-0.05/share.
See more from Benzinga
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
